Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N. Modica S, et al. Among authors: de luca a. J Antimicrob Chemother. 2020 Jan 1;75(1):194-199. doi: 10.1093/jac/dkz424. J Antimicrob Chemother. 2020. PMID: 31605107
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group. Trotta MP, et al. Among authors: de luca a. AIDS. 2003 May 2;17(7):1099-102. doi: 10.1097/00002030-200305020-00026. AIDS. 2003. PMID: 12700467
Interpretation systems for genotypic drug resistance of HIV-1.
De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, Perno CF, Cauda R. De Luca A, et al. Scand J Infect Dis Suppl. 2003;106:29-34. doi: 10.1080/03008870310009623. Scand J Infect Dis Suppl. 2003. PMID: 15000579 Review.
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Among authors: de luca a. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Di Giambenedetto S, Bacarelli A, Pinnetti C, Colafigli M, Prosperi M, Gatti G, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: de luca a. Scand J Infect Dis. 2007;39(9):813-8. doi: 10.1080/00365540701367728. Scand J Infect Dis. 2007. PMID: 17701721
2,256 results